Abstract
Pharmaceutical Quality Systems (PQS) based on ICH Q10 provide a formal framework for quality management, yet persistent quality failures, data integrity concerns, and regulatory observations indicate that structural compliance alone does not ensure effective performance. This narrative synthesis examines how human behavior contributes to PQS effectiveness and proposes that quality culture can be understood as the behavioral infrastructure through which PQS is enacted in practice.Through safety science, decision theory, organizational culture research, and published FDA Quality Management Maturity (QMM) materials, this paper explores how cognitive bias, normalization of deviance, psychological safety, and leadership signals influence core PQS elements, including process monitoring, deviation and CAPA management, change control, and management review. The synthesis proposes that differences in behavioral maturity may help explain why sites with comparable structural systems achieve different outcomes, while recognizing that this relationship is shaped by context, workload, incentives, and governance.A people‑systems model is introduced to describe how culture, behavior, and PQS structure interact to support sustained control and learning. The paper outlines practical implications for organizations seeking to strengthen behavioral indicators of PQS performance and suggests potential enhancements to regulatory inspection approaches, in which regulators interpret adaptive capacity and behavioral maturity primarily through objective evidence (for example, investigation depth, management review outputs, and CAPA effectiveness) alongside existing structural checks.